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An Unusual Treatment for  
Chronic Myelomonocytic Leukemia 
 Eric Warner, MSIII, Neil Palmisiano, MD
ABSTRACT
Chronic myelomonocytic leukemia is a rare, aggressive, 
chronic leukemia that frequently progresses to acute 
myeloid leukemia. For younger patients, treatment 
ideally involves bone marrow transplant, and, if not a 
candidate, hydroxyurea or hypomethylating agents are 
the standard of care for symptomatic patients. Here, we 
present an unusual treatment of a patient with chronic 
myelomonocytic leukemia (CMML) characterized by 
atypical mutations in IDH2 and NPM-1 using Venetoclax 
and a hypomethylating agent with complete response. 
INTRODUCTION
Chronic myelomonocytic leukemia has features of both 
myelodysplastic syndrome and myeloproliferative 
neoplasms. Characterized by an increase in circulating 
monocytes, the disease frequently progresses to acute 
myeloid leukemia (AML) and is the most aggressive 
chronic leukemia. Clonal cytogenetic abnormalities are 
found in approximately 30% of patients, most commonly 
trisomy 8, trisomy 21, monosomy 7 and del7q, and other 
complex karyotypes.1 For younger, fit patients, treatment 
ideally involves bone marrow transplant. If not a 
candidate, cytoreductive strategies using hydroxyurea 
or hypomethylating agents (HMA) are the standard of 
care for symptomatic patients. Because of the rarity of 
this disease, advancement of treatment strategies outside 
of transplant have been few.2 This case is presented to 
demonstrate an unusual treatment for CMML with IDH2 
mutation using Venetoclax and an HMA.
CASE PRESENTATION
A 76-year-old female with a past medical history of an 
extraosseous chondrosarcoma status-post resection 
thirty years prior, hypertension, hyperlipidemia, and 
hypothyroidism presented to her primary care physician 
with fatigue, two weeks of dyspnea on exertion, 
lightheadedness, and nausea. The patient’s primary care 
physician ordered a complete blood count, which was 
significant for a hemoglobin of 6.8 g/dl and she was 
instructed to go to the Emergency Room for workup. In 
the ER, the patient was afebrile, and her vital signs were 
all within normal limits. On exam, she was noted to have 
a 3/6 systolic ejection murmur. Her lungs were clear to 
auscultation bilaterally and she did not have any skin 
abnormalities. She was given a transfusion of packed red 
blood cells and her hemoglobin responded appropriately. 
However, she was found to have thrombocytopenia and 
a leukocytosis with an absolute monocyte count of 
5800 cells/uL (16% of the differential), a total white blood 
cell count of 36,400 cells/uL, a platelet count of 52,000 
per/uL and no eosinophilia. 
After being discharged, the patient was seen by oncology 
and underwent a bone marrow biopsy. Pathology 
showed hypercellular marrow (95%) with trilineage 
proliferation, 10% monocytes and 5-10% blasts with less 
than 10% dysplasia. Flow cytometry, cytogenetics and 
Next-Generation Sequencing were unable to be 
performed due to an inadequate sample. Peripheral 
blood was then analyzed which showed 16% monocytes, 
7% blasts and flow cytometry positive for CD4, CD11c, 
CD13, CD33, CD34, CD38, CD64, HLA-DR and CD117. 
Cytogenetics showed a normal female karyotype and 
was negative for BCR/ABL rearrangement. Mutational 
analysis was positive for IDH2, DNMT3A and NPM1 and 
was negative for JAK2, CALR and MPL. She was 
subsequently diagnosed with CMML, given her monocytic 
predominance and flow cytometry. Due to her excellent 
functional status (ECOG score of 1), curative treatment 
with cytoreductive agents and bone marrow transplant 
was pursued. Because of her NPM-1 and IDH2 mutation, 
it was decided that a regimen consisting of Decitabine 
and Venetoclax was appropriate. She began treatment in 
early February 2019 and, after two cycles, a biopsy was 
repeated, which showed only 9% abnormal myelocytes 
and no blasts. The regimen was well-tolerated by the 
patient and by June she was in complete response (CR) 
with no complications from treatment. She underwent 
another biopsy prior to transplant which showed 
hypocellular marrow with less than 1% monocytes and 
blasts. She then underwent non-myeloablative bone 
marrow transplant in November and, as of last follow-up 
112 days later, is in recovery. Bone marrow biopsy 
post-transplant showed normocellular marrow with no 
increase in abnormal monocytes. 
DISCUSSION 
Chronic myelomonocytic leukemia is diagnosed based 
on a peripheral monocyte count above 10%, in addition 
to bone marrow dysplasia. It frequently progresses to an 
acute leukemia in up to 20% of cases.3 The median age at 
onset is during the early seventh decade of life, and it has 
a slight male preference. There are several classification 
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systems including the World Health Organization classifi-
cation and the Mayo prognostic model, however the most 
commonly used is the CMML-specific prognostic scoring 
system (CPSS). The CPSS classifies patients into various risk 
categories using their CMML FAB type, cytogenetics, red 
blood cell transfusion dependence and, WHO subtyping 
based on the percentage of blasts in the periphery and 
bone marrow. For low risk patients the median survival is 
6 years, for high risk patients it is just 5 months.1
The most common mutations in CMML have differing 
mechanisms, including epigenetic control of methylation 
(TET2 60%), chromatin modulating (ASXL1 40%), cell 
signaling pathways (RAS pathway 30%) and mRNA splicing 
(SRSF2 50%). ASXL1 has been shown to correlate with 
survival. Mutations in IDH1 or IDH2 are uncommon in 
CMML, occurring in less than 5% of patients.4 Although 
rare in CMML, approximately 15% of patients with AML 
have a mutation in IDH. Normally IDH is involved in the 
citric acid cycle and metabolizes isocitrate to 5-alpha-
ketoglutarate. When IDH is mutated, it gives rise to a new 
metabolic product: 2-hydroxyglutarate (2-HG). 2-HG 
accumulates and inhibits other enzymes including TET2 
and JMJC, both epigenetic modifiers that can lead to 
leukemogenesis.5 Cells following this pathway become 
dependent on the anti-apoptotic gene Bcl-2 for survival.6
Due to its association with epigenetic dysregulation, the 
standard of care for CMML is a hypomethylating agent, 
specifically azacitidine or decitabine. These medications 
work by demethylating and subsequently allowing 
expression of hypermethylated tumor suppressor genes.7 
Unfortunately, only 50% of patients respond to these 
agents, with less than 20% achieving complete response 
to these agents alone.1 HMAs are also frequently used in 
patients with AML who are not candidates for standard 
chemotherapy induction. Unfortunately, response rates in 
most studies of patients with AML show a complete 
response in only approximately 20%.8 In more recent 
studies, patients over the age of 65 with AML were given 
the Bcl-2 inhibitor Venetoclax in addition to an HMA. 
Twenty-four percent of these patients achieved CR, with 
an additional 43% achieving CR with incomplete cell 
count recovery.9 To our knowledge, there have been no 
studies using HMAs plus Venetoclax in patients with 
CMML, however, Venetoclax has been shown to have 
efficacy in CLL, AML, and ALL, particularly in patients with 
IDH mutations.10 Although this is a relatively rare mutation 
in CMML, further study of this treatment regimen is 
warranted in patients who express IDH mutations in 
CMML and other MDS/MPNs. 
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